Royalty Report: Drugs, Cancer, Antibody – Collection: 369406

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Cancer
  • Antibody
  • Biotechnology
  • Drug Discovery
  • cell therapy
  • Disease
  • Proteins
  • Diagnostic
  • Therapeutic
  • Vaccine
  • Cell Line

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369406

License Grant
Licensor grants to Licensee of Germany an exclusive, worldwide license and sublicense, as applicable,  under the Licensor Technology to research, Develop, make, have made, import, export, use and Commercialize Licensed Products solely in and for the Field in the Territory.
License Property
Compound means
—  sonepcizumab, a humanized monoclonal antibody having the sequence described in any formulation,
—  any human, murine, chimera or other version thereof, and/or,
—  any modification, derivative, fragment or any conjugate of the compounds, in each case which binds with, and scavenges or otherwise modulates the activity of, S1P.

S1P means the target sphingosine-1-phosphate.

iSONEP means the ocular formulation of sonepcizumab which Licensor is developing, as of the Effective Date, for ocular lndications under the trademark iSONEPâ„¢.

Ocular Product means iSONEP and any other pharmaceutical product containing or comprising the Compound that is formulated and intended for use for ocular Indications.

Field of Use
ASONEP, a Phase I monoclonal antibody currently being evaluated for the treatment of various cancer types.

ASONEP is a humanized monoclonal antibody that neutralizes S1P, a bioactive lipid that stimulates tumor cell migration, invasion and survival and also promotes angiogenesis, i.e. growth of new blood vessels. S1P has been highly correlated with the development of drug resistance in various cancer types.

The Field of use means all prophylactic, palliative, therapeutic and diagnostic uses for any human or animal disease or condition; provided, however, that the Field shall exclude all prophylactic, palliative, therapeutic and diagnostic uses for any human or animal ocular Indications, and, all non-in-vivo diagnostic uses for any human or animal cardiovascular Indication.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 266837

License Grant
For the Research License Grants, Licensor shall automatically be deemed to have granted to Licensee a non-exclusive, worldwide license under the Licensor Technology solely to conduct the Research Program.

For the Exclusive License Grants, with respect to the First Exclusive Antigen, and the Option Exercise Fee  with respect to the Second Exclusive Antigen, and commencing as of the date Licensor has received the ADC Access Fee or Option Exercise Fee, as the case may be, from Licensee, Licensor shall automatically be deemed to have granted to Licensee an exclusive, even as to Licensor, license under the Licensor Technology, with the right to sublicense to discover, develop, have developed, make, have made, import, use, offer for sale, and sell Licensed Products that bind specifically to the Exclusive Antigen within the Field in the Territory.

For the Grant of Option, Licensor hereby grants Licensee an option to obtain the Exclusive License of this Agreement to the Second Exclusive Antigen during the Option Period.

For the Replacement Right; Dropped Antigen,  Licensee shall have the right to designate the first exclusive antigen as a Dropped Antigen for purposes of this Agreement by providing Licensor with written notice of same.  Licensee shall have the right to designate one (1) additional Designated Antigen as a replacement for the Dropped Antigen in accordance with  the procedure.

License Property
The patents relate to tumor inhibitors.

The patent applications include Pentapeptide Compounds and uses related thereto; Drug Conjugates and their uses for Treating Cancer, an Autoimmune Disease or an Infectious Disease; and, Monomethylvaline Compound Capable of Conjugation to Ligands.

ADC technology can be widely employed to increase the therapeutic potential of monoclonal antibodies through stable attachment to cell-killing drug payloads.

Field of Use
Field means the treatment and diagnosis of conditions and diseases in humans and animals; provided that with respect to the use of the BMS Technology the Field shall be limited to monoclonal antibody targeting applications.

The proprietary ADC technology for use with Licensee's proprietary antibodies for the treatment of cancer.

IPSCIO Record ID: 6797

License Grant
Licensor hereby grants to Licensee a right and license or, in the case of Patents licensed to Licensor under the Licensor In-Licenses, a sublicense, under the Licensed Technology, to make, have made, use, offer to sell, sell and have sold Products except as set forth in this agreement in the relevant Field, and in the Territory.
License Property
Table 1 BR96sFv-PE40 Program

The following patents and patent applications, together with the know-how related thereto, constitute the BR96 sFV-PE40 Program

Patent
  
Description
License Type

Number
Number

57,444
5,491,088
  
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive

459,354

  
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive

Table 2 BR96/Drug Conjugate Program

Application
Patent
  
Description
License Type

Number
Number

353,729
5,122,368
  
Linker chemistry having an acylhydrazone linkage through C13 keto group of anthracycline to nonimmunoglobulin ligand. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers

96,628

  
Acylhydrazone linkage through C13 keto group of anthracycline to immunoglobulin. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers

824,951
5,622,929
  
Anthrecycline ligand conjugates where linkage is an acylhydrazone through C13 keto position of anthracycline. Linker also contains succinimido moiety. Chemistry is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

08/468,162
5,606,017
  
Anthracycline intermediate having acylhydrazone linkage through C13 keto position of anthracycline and a Michael Addition Receptor. Intermediate in conjugation used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

08/469,840

  
Process for conjugation using intermediate above with reduced immunoglobulin to increase total drug to antibody yield. Process is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

62,366

  
Enzyme cleavable peptide linker for making cytotoxic drug ligand conjugates. Linkers are used to make second generation BR96-Dox.
Partially-Exclusive for Linkers

57,444
5,491,088
  
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive

77,253

  
Immunoconjugates of murine monoclonal antibody BR96, chimeric BR96 and other recombinant antigen binding fragments. Includes single chain and bispecific recombinant constructs.
Exclusive

333,840

  
Methods of treating human carcinoma by administering murine BR96, chimeric BR96 or any recombinant antigen binding construct either by itself or conjugates with various agents. Also includes diagnostic kits.
Exclusive

459,354

  
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive

08/285,936

  
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive

08/487,860

  
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive

60/030/367

  
Branched peptide linker for linking thiol group on targeting ligand to two or more drug moieties.
Partially-Exclusive for Linkers

5,204,244
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

5,202,238
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

5,482,856
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

Table 3 G28-5 SfV/Immunotixin Program

The patents and patent applications (the “Washington Patents”), together with the know-how related thereto, sublicensed under the Washington Agreement constitute the G28-5 sFv/Immunotoxin Program. [Exclusive]

Table 4 BD1 Program

The following patents and patent applications, together with the know-how related thereto, constitute the BD1 Program

Application
Patent
Description
License Type

Number
Number

08/245,754
5,541,110
Isolated oligonucleotide sequence encoding Bryodin 1, recombinant vectors and plasmids, and transfected host cells.
Exclusive

08/597,731

Methods for the recombinant production of Bryodin 1 and Bryodin 1-ligand fusion proteins.
Exclusive

08/324,301
5,597,569
Ribosome-inactivating protein Bryodin 2 in an isolated form, linked to a ligand as a conjugate or a fusion protein, pharmaceutical compositions, nucleotide sequence, transfected host cells and recombinant production.
Exclusive

Table 5 ADEPT Program

The following patents and patent applications, together with the know-how related thereto, constitute the ADEPT Program

Application

Number
Patent
Description
License Type

(filed 5/7/96)
Number

Recombinant L49sFv-¨ lactamase fusion proteins which recognize p97 melanoma antigen and activate-cephalosporin derivatized prodrug molecules.
Exclusive

211,301
4,975,278
Methods for delivering cytotoxic agents to tumor cells by administering an effective amount of at least one antibody-enzyme conjugate, wherein the antibody is specific for a tumor associated antigen and the enzyme converts at least one weakly cytotoxic prodrug to its corresponding cytotoxic parental form; and the administration of an effective amount of the prodrug.
Non-Exclusive

Table 6 Residual Program

The following patents and patent applications, together with the know-how related thereto, constitute the Residual Program

Application
Patent
Description
License Type

Number
Number

684,759
4,935,495
Monoclonal antibodies, Fab, F(ab1)2 or Fv fragments thereof which compete for binding with L6 to its antigen.
Partially-Exclusive for Cancer

776,321
4,906,562
Methods for detecting malignancy using L6 or other monoclonal antibodies or fragments thereof which compete with L6 for binding to its antigen.
Exclusive

523,309
5,091,177
Method for reducing population of tumor cells using L6 or monoclonal antibodies which compete for binding with L6 to its antigen.
Exclusive

443,696
5,242,824
Monoclonal antibody BR64 and antigen binding fragments thereof.
Exclusive

08/726,528

Monoclonal antibodies and recombinant antigen binding molecules which recognize the G733-1 but not G733-2 antigen. Specifically BR110.
Partially-Exclusive for Cancer

527,227
5,165,922
Method of treating breast carcinoma in an unresponsive patient by first administering monoclonal antibody L6 followed by administration of a chemotherapeutic agent.
Exclusive

5,663,158
Method for treating vascular leak syndrome.
Non-Exclusive

The Residual Program also includes antibodies L6, L49, BR64, BR110, OV578.1 and OV569.1 [Exclusive]

Field of Use
Field shall be the treatment and diagnosis of cancer in humans.

The Field with respect to Licensed Technology for which Licensee is granted a right and license that is partially exclusive shall be

(i) if this Agreement indicates that such license is partially exclusive for linkers, all monoclonal antibody targeting applications; or (ii) if the agreement indicates that such license is partially exclusive for cancer, the treatment and diagnosis of cancer in humans. The Field with respect to Licensed Technology for which Licensee is granted a right and license that is non-exclusive shall be the treatment and diagnosis of cancer in humans. Notwithstanding the foregoing, the Field with respect to the G28-5 Licensed Technology shall be for the use of the antibody G28-5 fused with a toxin for the treatment of cancer in humans.

IPSCIO Record ID: 256253

License Grant
With this agreement, the French Licensee will receive an exclusive worldwide license to develop, manufacture and commercialize MM-121. Licensor will retain potential co-promotion rights in the United States.

Licensor grants the French Licensee an exclusive right and license, with the right to grant sub licenses, under Licensed Technology and Licensed Patent Rights, including Licensors rights to Joint Technology and Joint Patent Rights, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Compounds and Licensed Products in the Field in the Territory.

This agreement includes a non-exclusive grant-back from Licensee to Licensor.

License Property
Licensor has rights to a monoclonal antibody, known as MM-121, with binding affinity to the ErbB3 protein.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a member of the epidermal growth factor (EGF) receptor family.  

The Collaboration Compound means MM121, or, any antibody fragment of MM-121, including any Fab, F(ab)2, Fv, and scFv fragments, or the primary molecular target of which is ErbB3.  ErbB3, also known as HER3, is a transmembrane receptor belonging to the epidermal growth factor (EGF) receptor family.

MM-121 is currently in Phase 1 clinical testing.

Licensed Technology means the Diagnostic Technology and the Therapeutic Technology.

Field of Use
Field means all human and veterinary fields of use, including therapeutic, prophylactic and diagnostic uses in all possible indications.

MM-121 a genetically engineered antibody designed to block a receptor on cells known as ErbB3. That’s thought to be an important new target for cancer drugs, because it’s a member of the epidermal growth factor receptor family of proteins, which are known to amplify cell proliferation that can give rise to out-of-control tumors.

The ErbB3 receptor is a novel target known to be a key mediator of signaling in the ErbB pathway (also known as the EGFR or HER pathway) – a signaling network that impacts a broad array of cancers. By targeting ErbB3, MM-121 is believed to have a broad application across cancer as both a monotherapy and in combination with other therapeutics.

IPSCIO Record ID: 357950

License Grant
Licensor grants to Licensee, an affiliate, an exclusive, worldwide right and license, with the right to sublicense, under the Licensed Patents to research, Develop, manufacture, have manufactured, use, import and Commercialize and have Commercialized the Licensed Products, in and for the Field and to practice and have practiced any Licensed Processes, in and for the Field.

Effective immediately at the time Licensee is no longer deemed to be an Affiliate of Licensor, Licensor grants Licensee a non-exclusive license under Licensed rights in and to the Licensed Materials solely in support of the exercise of Licensees license rights.  Licensee shall not have the right and shall be prohibited from selling, transferring, or distributing the Licensed Materials to end users, except in the case where such end users are Licensor Affiliates or Sub licensees under this Agreement.

License Property
Licensor has rights to the Licensed Patents and Materials as granted by Dana Farber Cancer Institute.

Antibody means any antibody, any gene expressing such an antibody, any hybridoma producing such antibody, or any fragment, variant, derivative or construct thereof, or antibody fusion protein produced therefrom, including PEDgylated or multimeric versions thereof, whether polyclonal, monoclonal, multi-specific antibodies, e.g., bi-specific antibodies, human, humanized, chimeric, murine, synthetic, or from any other source, including without limitation, the full immunoglobin molecules (e.g. the IgG, IgM,IgE, IgA, and IgD molecules), and the antigen binding portions including Fab, Fab, F(ab)2, Fv, dAb, and CDR fragments, chimeric antibodies, diabodies, polypeptides, linear antibodies and single-chain antibodies (scFv) that contain any portion of an immunoglobulin that is sufficient to confer specific binding to an antigen.

The agreement is to develop and commercialize Licensor's fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

Field of Use
The Field means all prophylactic, palliative, therapeutic or diagnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemias, Lymphomas, Multiple Myeloma and Waldentroms Macroglobulemia, but specifically excluding use in chimeric antigen receptor technology. Additionally, upon exercise of the Autoimmune Option, the Field shall include the prevention, diagnosis and treatment of Autoimmune Diseases.

Autoimmune Diseases means any disease which results from a loss of immune tolerance to self-antigens, including without limitation multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, sjogren syndrome, celiac disease, Graves disease, myasthenia gravis, Type I diabetes, idiopathic thrombocytopenic purpura, pemphigus vulgaris, among others, including any presentation or manifestation thereof.

IPSCIO Record ID: 240615

License Grant
The Parties previously entered into an Amended and Restated Development and License Agreement governing the Parties’ joint development of anti-CD40 antibodies.

Licensor has discontinued the anti-CD40 antibody program thereunder, and Licensee now wishes to continue development of anti-CD40 antibodies on its own.

As of the effective date, the Prior Agreement is terminated in its entirety.

For the Grant under Licensor CD40 Know How,  Licensor grants a license under the Licensor CD40 Know How, to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

For the Grant under Licensor CD40 Patents, Licensor grants a license under the Licensor CD40 Patents, to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

For the Grant under Licensor Patents,  Licensor grants a license under the Licensor Patents, to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

For the Right to Use Materials and Technology,  Licensor grants a license under Licensors rights in the Materials and Technology, to use the Materials and Technology in the form supplied by Licensor to Licensee under this Agreement to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

License Property
Antibody means the humanized anti-CD40 monoclonal antibody designated by Licensor as PRO64553.

Anti-CD40 Antibody means any anti-CD40 antibody, including, without limitation, the Antibody, any variant, including, without limitation, humanized versions, or fragment, including, without limitation, single-chain versions, of any such anti-CD40 antibody, conjugates, including conjugates with radionuclides, toxins or other compounds, of any of the foregoing which, in each case, was developed by Licensor in its performance of the Prior Agreement.

Licensor CD40 Patents include, no. 60/280805 and no. 10/099,818 entitled Combination Therapy.

Licensed Product means any product containing an Anti-CD40 Antibody.

SGN-40 is a humanized monoclonal antibody that targets the CD40 antigen, which is highly expressed on most B lineage hematologic malignancies including non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, renal and ovarian cancer, and may play a role in immunologic diseases.

Field of Use
SGN-40 is a humanized monoclonal antibody currently in Phase I and Phase II clinical trials for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

IPSCIO Record ID: 4497

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses under Licensor's Technology to research, develop, make, have made, use, sell, offer for sale, export and import Licensor's Antibodies and Products in the Field in the Territory.
The license grants rights to all Licensor's mAbs (monoclonal antibodies) in the field of influenza discovered from their CellSpot platform.
License Property
The license provides Licensee with three fully human mAbs that bind, neutralize and protect animals from all strains of H1, H3 and B influenza, and that will also cross bind, neutralize and protect animals from all other seasonal or pandemic influenza strains that may arise (including H5N1 and H7N9).

“Antibody” means any antibody or protein comprising at least one CDR portion thereof (including multi-specific antibodies, single chain antibodies, antibody fragments, domain antibodies and conjugated antibodies) and/or similar binding protein (such as an adnectin), whether human, humanized, chimeric, murine, synthetic or from any other source.

Field of Use
“Field” means all uses for the diagnosis, treatment or prevention of influenza.

IPSCIO Record ID: 227272

License Grant
Licensor Institute, a nonprofit American medical research facility, grants an exclusive, worldwide license, including the right to sublicense, to Licensors Technology and under Licensors Patent Rights, to make, to have made, to import, to use, to offer for sale, and to sell Licensed Products in the Field.

This agreement also contains a non-exclusive grant back from Licensee to Licensor.

License Property
The patents are for Methods and Compositions for Enhancing Angiogenesis, Methods and Compositions for Modulation T-cell Activation and Uses thereof, and, Methods for Detecting Vasculopathies and Tumors.

Technology relates to angiogenesis, including anti-angiogenic diagnostic applications.
Angiogenesis means the growth of new blood vessels. Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.

Field of Use
The term Field shall mean human therapeutic and diagnostic applications and shall specifically exclude any Agricultural Product.

Licensee is engaged in research and development of biotechnology and pharmaceutical products which regulate the growth of new blood vessels.

IPSCIO Record ID: 279345

License Grant
The English Licensor hereby grants to the English Licensee (i) a non-exclusive worldwide sublicense, with the right to grant further Sublicenses, under the Licensed Patent Rights to make, have made, use, import, offer for sale, and/or sell Licensed Products; and (ii) an exclusive worldwide license, with the right to grant Sublicenses, under the Licensor IP to make, have made, use, import, offer for sale, and/or sell Licensed Products.
License Property
US Patent #5,225,539 – Recombinant altered antibodies and methods of making altered antibodies

Licensed Product shall mean a product comprising a Humanized Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensor IP or Licensor Inventions.  The term “Licensed Product” does not include chimeric antibodies or murine antibodies.

Humanized Antibody shall mean an antibody that binds to Sphingosine-1-phosphate and is made by Licensor under this Agreement, the antibody comprising murine complementarity determining regions derived from Sphingomabâ„¢ together with human framework regions, and any modifications thereof.

Licensor IP shall mean (i) any Licensor Invention and (ii) all patented and non-patented proprietary technology and information, in any form whatsoever, that is (a) necessary or useful for making and using the Licensed Products, without regard to whether or not the technology or information is patentable; (b) owned, controlled, or developed by Licensor, as of the Effective Date or hereafter during the term of this Agreement; and (c) provided by Licensor to Licensee hereunder, including, but not limited to discoveries, formulae, materials, practices, methods, knowledge, know-how, processes, trade secrets, ideas, concepts, manufacturing, engineering, standard operating procedures, flow diagrams and charts, quality assurance, quality control data, technical data, manufacturing technology, research data and records, and all other confidential or proprietary technical and business information relating to the humanization of murine antibodies, generation of chimeric antibodies, or any gene expression vectors used in such methods and all improvements or modifications thereto.  For purposes of clarity, Licensor IP includes Licensor Inventions that satisfy (a), (b) and (c), above, while Licensor IP does not include Licensed Patent Rights as defined hereunder.

Licensor Invention shall mean any discovery or invention to the extent (i) made or conceived or reduced to practice by or on behalf of Licensor in the performance of the humanization of Licensees Sphingomabâ„¢ antibody under this Agreement, whether or not patentable, and (ii) covering only generally applicable methods or techniques for humanizing antibody proteins or for constructing a vector or reagent used to humanize or express an antibody.

Field of Use
Licensee’s lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), an innovative and validated cancer target.

Sphingomabâ„¢ is the original mouse version of this monoclonal antibody.

IPSCIO Record ID: 369313

License Grant
Licensor, a non-profit cancer treatment and research institution, grants the exclusive right and license, with the right to sublicense, to make, have made, use, lease and sell the Licensed Products in the Territory for the Field of Use.
License Property
The Invention shall mean the inventions claimed or described in Patent Rights titled Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma associated antigen.
Field of Use
Licensee is developing the MUC-1 peptide-based vaccine BLP-25 for the potential treatment of cancer. It is in phase II trials for non-small cell lung cancer (NSCLC). The MUC-1 mucin secreted by cancer cells has been shown to decrease the activity of certain immune response cells, including killer T-cells, and can inhibit the immune T-cell response by > 70%. BLP-25 is designed to target an immune response to the MUC-1 mucin that is shown by > 90% of common solid tumors.

The Field of Use shall mean in vivo, ex vivo, or in vitro prophylactic or therapeutic uses of Licensed Product in the treatment or prevention of cancer in humans.

IPSCIO Record ID: 356291

License Grant
For the General Grant to the German Licensee, Licensor grants an exclusive license, including the right to sublicense through multiple tiers, under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to Develop the Product in the Licensees Territory in the Field; and during the Term, an exclusive license, including the right to sublicense through multiple tiers, under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to Commercialize the Product in the Field in the Licensees Territory; and during the Term, a non-exclusive, perpetual, worldwide license under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to perform Development Activities in the Licensor Territory solely in accordance with the Development Plan and for Sole-Funded Activities by Licensee.

For the Manufacturing Grant to Licensee, Licensor grants a co-exclusive license, including the right to sublicense through multiple tiers, under the Licensor Manufacturing Technology, Licensors interest in the Joint Technology, Licensor Patents and the Licensor Platform Technology, to Manufacture the Product for Development worldwide in the Field and for Commercialization in the Field in the Licensee Territory.

By this agreement, Licensor will have the exclusive commercialization rights in the United States and Canada and Licensee will have the exclusive commercialization rights in the rest of the world.

License Property
Licensor has developed and is currently further developing the novel compound xx414.

Compound xx414 means a bispecific polypeptide containing a Prostate Specific Membrane Antigen or PSMA Binding derived from murine antibody 107-1A4 and a CD3 Binding Domain derived from murine antibody CRIS-7 (xx414), and any back-up or follow-on compound comprised of a PSMA Binding Domain with or without other Binding Domains, including both a PSMA Binding Domain and a CD3 Binding Domain or both a PSMA Binding Domain and a Binding Domain other than CD3 Binding Domain; and any modification or derivative of the foregoing (including conjugated or mono/multi-specific forms thereof).

CD3 Antigen means the T cell receptor (TCR) complex or any one or more of the CD3 group of cell surface molecules found on T-cells, including TCRa, TCRb, CD3y, CD3d, and CD3e.

CD3 Binding Domain means a Binding Domain that binds the CD3 Antigen and which has greater binding selectivity for the CD3 Antigen versus other antigens (and, for purposes of this definition, disregarding any residual binding activity).

Product Inventions means all Inventions relating to a PSMA Binding Domain, including Inventions relating to composition of matter, method of use and method of manufacture of the Product.

PSMA Antigen means prostate specific membrane antigen (PSMA), also known as the enzyme glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), or NAAG peptidase.

The patents include
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods,
CD3 Binding Polypeptides, Single Chain Multivalent Binding Proteins with Effector Function, Heterodimer Binding Proteins and Uses Thereof, and, Polypeptides Heterodimers and Uses Thereof.

Field of Use
The collaboration agreement is for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, which activates host T-cell immunity specifically against cancer cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells.

Field means all fields of use, including therapeutic, palliative, prophylactic, diagnostic and research use, in human and animals.

Licensee has significant experience in the development of pharmaceutical products;

IPSCIO Record ID: 369305

License Grant
Licensor, a nonprofit cancer research institute, hereby grants to Licensee and Licensee accepts subject to the terms and conditions hereof the following licenses
(a) a non-exclusive license to use, possess, culture and employ the Licensed Cell Line at its business premises solely in the United States;
(b) a worldwide, non-exclusive license to the Licensed Monoclonal Antibody to make and have made, to use, to sell, have sold and offer for sale the Licensed Products and the Licensed Services in the field for the term of this Agreement (collectively the Licenses). Notwithstanding any other provision of this Agreement, (1) Licensee and its Affiliates shall not use the Licensed Cell Line or Licensed Monoclonal Antibody for any purpose other than that expressly described in this Agreement (2) shall not transfer the Licensed Cell Line to any third party or affiliate for any purpose except to a sublicensee as provided in this Agreement and (3) shall in no event transfer the Licensed Cell Line outside of the United States.

Licensee shall have no right or power to grant sublicenses of the Licensed Cell Line, except Licensee shall have the right to sublicense third parties to make the Licensed Monoclonal Antibody on behalf of Licensee solely for the use of Licensee, its affiliates and sublicensees subject to Licensor prior written consent.

License Property
Licensed Cell Line means the hybridoma  cell line BC3 described in Anasetti, C et. al., 'Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen', J Exp. Med., l 72, pp. 1691-1700 (1990) and Anasetti, C. et al., Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody, Transplantation, 54, pp. 844~85 1 (1992) and all progeny, clones, derivatives and modifications thereof. Such derivatives and modifications shall not include antibodies which are not derived from or developed using the Licensed Materials and which have been entirely made with the use of information or materials available in the public domain.

Licensed Monoclonal Antibody means the monoclonal antibody BC3 and antigen binding fragments thereof, produced by or derived from the Licensed Cell Line.

Licensed Products means any product, including reagents, devices, kits and packages that contain, or are derived from, or result from the use of the Licensed Monoclonal Antibody including without limitation beads coated with the Licensed Monoclonal Antibody either by itself or in combination with other antibodies. Licensed Products does not include the Licensed Cell Line.

Licensed Services means any service performed for a third party using a Licensed Product or the Licensed Monoclonal Antibody. Services performed on biological materials from a single patient which are clinically defined to constitute a single course of treatment shall constitute the performance of a single Licensed Service procedure for purposes of this Agreement.

Field of Use
IP relates to using the monoclonal antibody that binds to the CD3 molecule for T cell stimulation for ex vivo therapeutic and research uses other than cell separation and selection.  T cells remain in a resting state until they become activated upon encountering antigens expressed by infected cells or tumor cells.

Field means any ex-vivo use for human prophylactic, therapeutic and research applications, excluding cell separation and selection applications.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.